Imagine a potential vaccine to inoculate against Alzheimer disease which may also be treatment:

It is not uncommon in the western world to treat symptoms of a disease rather than the underlying condition itself. This is may also be the case within the Alzheimers disease state. Although aging is still considered to be the most important risk factor for the development of Alzheimer disease (AD), many other factors associated with aging have been proposed as additional independent or interactive causes.

It is likely that most age-related diseases could be attributed, at least in part, to an imbalance and senescence of the immune system. As of this writing, all FDA approved drugs for Alzheimer disease (AD) only address symptoms and have not proven t0 benefit the impaired immune system in AD. This is where we began our quest, for at least one of the underlying causes of this disease state. It was also the motivation of our team to develop a unique approach for combatting AD, namely through immunotherapy.

Recent progress in the treatment of neurodegenerative diseases, such as AD, has been demonstrated in animal and clinical trials through the measurement of neuropathological and cognitive/behavioral endpoints. Both active and passive immunotherapies have been shown to slow down, to some degree, the progress of disease. Our novel immune-based methodology attempts to inhibit the natural process of immunological aging by restoring the balance of immune system through immunomodulation. It is reasoned that strategies to strengthen the immune system in the aged, who are most susceptible to the development of AD, could greatly enhance the effectiveness of immune-based approaches against AD.

What is Immunotherapy?

In a nutshell, Immunotherapy is a form of treatment that utilizes ones own immune system to attack certain types of disease by inducing, enhancing, or suppressing an immune response. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

Classically there are two main approaches when utilizing immunotherapy: The first is to stimulate ones own immune system to ramp up and push harder against those rogue cells or teach them to better identify them. The second, is to enhance the immune system by giving it some new components, like synthetic immune system proteins.

Immunotherapy can be crafted to work in different ways. One method might include more of a shotgun approach giving the body’s immune system a boost and generally making the whole system stronger. Another might be to focus on and attack specific cells as more of a rifle approach. Unfortunately, not all immunotherapy works equally well on all types disease and must be tweaked or combined with other treatment methods to elicit a positive response.

CAO22W – Novel adjuvant-free vaccination to aid in the battle against AD and Aẞ plaque buildup

The University of South Florida was granted a patent related to this technology (USPTO # 8,188,046) in 2012, and this patent is exclusively licensed to Alzamend Neuro, Inc. The company’s goal is to move this technology out of the research and preclinical stage and into a path toward commercialization.